Compounded GLP-1 medications include the same active ingredient (semaglutide) as Wegovy, Ozempic, and Rybelsus
The drugs have been credited with reshaping not only individual health but also corporate strategies, food industry investments, and public health discussions about obesity as a chronic disease requiring medical treatment
The Broader Enforcement Campaign Against Bootleg GLP-1 Cease-and-desist letters are only one tool in an aggressive, nationwide movement to stop the illegal compounding of GLP-1s
In a clinical trial specifically designed for weight loss, participants using Semaglutide GLP-1 experienced an average loss of up to 15% of their initial body weight over a 68-week period
However, remember that compounded medications are not covered by insurance, so the full cost comes out of pocket
Developed by Eli Lilly under the compound code LY3437943, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors a mechanism that distinguishes it from currently approved agents such as semaglutide and tirzepatide